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Would a cohort-level approach to cost-effectiveness 
modelling have led to a different decision in an 
important NICE appraisal for obesity patients?
Methods
In 2017, the National Institute for Health and Care Excellence (NICE) 
appraised naltrexone-bupropion (NB32) + standard management (SM) 
versus SM alone for the treatment of adult obesity (TA494) based on a 
patient-level model originally implemented as a discretely integrated 
condition event (DICE) simulation1.
The Evidence Review Group (ERG) had concerns with how the 
implementation of the model affected its run time, limiting the ERG’s 
ability to simulate sufficient patients and probabilistic sensitivity analysis 
(PSA) iterations. This may have contributed to the NICE appraisal 
committee not recommending NB32 as an appropriate use of National 
Health Service (NHS) and Personal Social Services (PSS) resources, though 
a reimplemented version of the model in a non-DICE (within VBA) 
framework was accepted and used to inform Final Appraisal Determination.
This study aims at examining the impact of modelling the same decision 
problem using a (non-DICE) cohort-level approach.
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Conceptual modelling and literature reviews were conducted to develop a 
cohort-level model structure (Figure 1).
The model was a non-DICE, 40-state, probabilistic, cohort-level Markov 
model and was specified and constructed in Microsoft Excel®.
Data inputs and assumptions matched the NICE committee preferred 
approach based on available materials at time of replication.
Introduction and objectives
The mean PSA incremental cost-effectiveness ratio (ICER) from the cohort-
level model (£47,729) was higher than both the committee’s preferred ICER 
(£23,750), and the £30,000 upper limit of the NICE willingness-to-pay 
threshold range for technologies that are neither end of life nor highly 
specialised3.
For both models, results were highly sensitive to changes in the small 
estimated incremental health benefit (0.0195 versus 0.0434 quality-adjusted 
life-years [QALYs] for the cohort- and patient-level models, respectively).
Cohort- and patient-level model drivers were generally consistent, with 
monitoring and morbidity costs constituting the majority of overall costs, 
and treatment acquisition comprising the bulk of the incremental costs.
Results
Intrinsic differences between both modelling approaches contributed to 
differences in the model results (both in terms of total costs and QALYs, 
and hence the estimated ICERs).
The cohort-based probabilistic model was able to consider the main 
assumptions and inputs from the original model, however, an even more 
complex structure would be required to better capture patient 
heterogeneity in the memoryless Markov framework.
Data availability limited replication efforts, and so the findings of our study 
should be considered with caution.
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Key message: Cohort-level approach in modelling obesity (NICE TA494) could have led to similar recommendations, however our recreation indicates that 
the flexibility of the patient-level approach used in the submission was valuable in capturing patient heterogeneity and time-dependency,  though 
reimplementation in a non-DICE framework was necessary for acceptable model execution speed.
Main model assumptions
Upon model entry, no patients had a history of angina and/or diabetes 
other than Type 2 Diabetes Mellitus (T2DM).




































-Transition to ‘Dead’ can happen from any health state within any model cycle. Arrows removed for 
simplicity.
Change in body weight curves from the COR-I and COR-DM trials (the two 
main NB32 trials conducted in non-diabetic and diabetic population, 
respectively) were digitised to quantify the benefit from treatments at each 
cycle in terms of reductions in weight and body mass index (BMI).
BMI was linked to the risk to CV events via published time-to-event models 
by Ara et al., (2012)2, consistent with TA494.
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